StreetInsider.com News Articles

Form 144 AGILENT TECHNOLOGIES, Filed by: Dolsten Mikael

Fri, 04 Sep 2026 16:19:00 -0400

si-local-file:///var/storage/secattach/20260904/27030135.html

Agilent launches FDA-cleared S540MD slide scanner in the U.S.

Fri, 04 Sep 2026 08:01:53 -0400

Agilent Technologies (NYSE: A) has launched the Agilent S540MD Slide Scanner System in the United States following FDA clearance, according to a company statement. The whole slide imaging digital scanner is designed for high-volume pathology laboratories.

The S540MD offers capacity for up to 540 slides, continuous loading, and standard rack compatibility. The system includes automated scanning modes and advanced tissue detection. The scanner is the Agilent-branded version of the Hamamatsu NanoZoomer S540MD Slide Scanner System.

The U.S. launch follows the January 2026 introduction of the same system in select European markets. The product is now available in the United States and 14

Agilent Expands Digital Pathology Offering with U.S. Launch of the Agilent S540MD Slide Scanner System

Fri, 04 Sep 2026 08:00:00 -0400

The FDA-cleared system will strengthen Agilent's support for digital pathology laboratories

SANTA CLARA, Calif.--(BUSINESS WIRE)-- Agilent Technologies Inc. (NYSE: A) today announced the U.S. launch of the Agilent S540MD Slide Scanner System, a whole slide imaging (WSI) digital scanner, following FDA clearance. This launch underscores Agilent’s ongoing commitment to digital pathology, broadening its portfolio to address the increasing demand for high-throughput solutions in clinical laboratories.

Pathology laboratories continue to face increasing pressure to improve diagnostic efficiency, manage growing sample volumes, and prepare for the adoption of digital and AI-enabled workflows. As laboratories accelerate their

Agilent Expands Digital Pathology Offering with U.S. Launch of the Agilent S540MD Slide Scanner System

Fri, 04 Sep 2026 08:00:00 -0400

The FDA-cleared system will strengthen Agilent's support for digital pathology laboratories

Agilent (A) PT Raised to $180 at Baird

Thu, 03 Sep 2026 07:05:43 -0400

Baird analyst Catherine Schulte raised the price target on Agilent (NYSE: A) to $180.00 (from $169.00) while maintaining a Outperform rating.

Form S-4 AGILENT TECHNOLOGIES,

Tue, 01 Sep 2026 17:16:00 -0400

si-local-file:///var/storage/secattach/20260901/27013874.html

Agilent Technologies filed for proposed debt offering

Tue, 01 Sep 2026 17:15:06 -0400

Agilent Technologies on Tuesday filed for a proposed offering of debt securities.

Form S-3ASR AGILENT TECHNOLOGIES,

Tue, 01 Sep 2026 17:12:00 -0400

si-local-file:///var/storage/secattach/20260901/27013819.html

Form 10-Q AGILENT TECHNOLOGIES, For: Jul 31

Tue, 01 Sep 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260901/27012927.html

Agilent launches compact Cary 635 FTIR spectrometer

Tue, 01 Sep 2026 13:18:32 -0400

Agilent Technologies (NYSE: A) has launched the Cary 635 FTIR spectrometer, a compact Fourier transform infrared analysis instrument aimed at laboratory use across multiple industries.

According to a company statement, the Cary 635 is designed to occupy minimal bench space and can be repositioned at various points in a laboratory workflow. The instrument uses solid zinc selenide optical components intended to improve moisture resistance, and features permanently aligned optics to allow rapid interchange of sampling modules for analysis of solids, liquids, powders, and gases.

The spectrometer includes a nondynamic interferometer, which Agilent says requires minimal maintenance. An optional DialPath module is available

Agilent launches compact Cary 635 FTIR spectrometer

Tue, 01 Sep 2026 08:05:40 -0400

Agilent Technologies (NYSE: A) has launched the Cary 635 FTIR spectrometer, a compact Fourier transform infrared analysis instrument aimed at laboratory use across multiple industries.

According to the company, the instrument uses solid ZnSe optical components to improve moisture resistance and features permanently aligned optics that allow sampling modules to be swapped quickly. The system supports analysis of solids, liquids, powders, and gases through a modular architecture.

Agilent claims the Cary 635 is the smallest FTIR in its class. The instrument includes a nondynamic interferometer designed to reduce maintenance requirements and improve operational consistency.

The spectrometer ships with Agilent's MicroLab software, which provides

Agilent Introduces the Cary 635 FTIR Spectrometer

Tue, 01 Sep 2026 08:00:00 -0400

A compact, user-friendly system designed for today’s laboratory demands

SANTA CLARA, Calif.--(BUSINESS WIRE)-- Agilent Technologies, Inc. (NYSE: A) today announced the launch of the Agilent Cary 635 FTIR spectrometer, setting a new standard for compact, high-performance Fourier transform infrared (FTIR) analysis. Combining robust engineering, superior performance, and intuitive usability, the Cary 635 FTIR provides laboratories with a powerful solution that enhances reliability, boosts productivity, and delivers the versatility required for today’s analytical challenges.

Laboratories must continually balance the demand for reliable, efficient results with the need to conserve time, reduce costs, and optimize limited workspace.

Agilent Introduces the Cary 635 FTIR Spectrometer

Tue, 01 Sep 2026 08:00:00 -0400

A compact, user-friendly system designed for today’s laboratory demands

Laboratories must continually balance the demand for reliable, efficient results with the need to conserve time, reduce costs, and optimize limited workspace.

Agilent Introduces the Cary 635 FTIR Spectrometer

Tue, 01 Sep 2026 08:00:00 -0400

A compact, user-friendly system designed for today’s laboratory demands

Laboratories must continually balance the demand for reliable, efficient results with the need to conserve time, reduce costs, and optimize limited workspace.

Agilent Introduces the Cary 635 FTIR Spectrometer

Tue, 01 Sep 2026 08:00:00 -0400

A compact, user-friendly system designed for today’s laboratory demands

Laboratories must continually balance the demand for reliable, efficient results with the need to conserve time, reduce costs, and optimize limited workspace.

Agilent (A) PT Raised to $175 at HSBC

Tue, 01 Sep 2026 02:16:43 -0400

HSBC analyst Shubhangi Gupta raised the price target on Agilent (NYSE: A) to $175.00 (from $165.00) while maintaining a Buy rating.

Agilent (A) PT Raised to $180 at Wells Fargo

Fri, 28 Aug 2026 06:56:05 -0400

Wells Fargo analyst Evan Stampler raised the price target on Agilent (NYSE: A) to $180.00 (from $160.00) while maintaining a Overweight rating.

Agilent (A) PT Raised to $180 at Bernstein SocGen Group

Thu, 27 Aug 2026 09:30:26 -0400

(Updated - August 27, 2026 9:30 AM EDT)

Bernstein SocGen Group analyst Eve Burstein raised the price target on Agilent (NYSE: A) to $180.00 (from $155.00) while maintaining an Outperform rating.

The analyst commented: "Big beats on organic growth and adj. op margin; China recovery + reshoring tailwind coming faster than expected; Agilent reported a 3Q beat and raise Wednesday (PR, slides). Core organic growth of 7.3% was above guidance of 4.4%-5.9% and consensus of 5.4%. Margins beat handily (56.4% GM vs consensus of 54.2%, 28.3% OM and 27.2% OM ex-tariff refunds vs consensus of 26.4%). Overall EPS beat by 8.8% ($1.62

Agilent (A) PT Raised to $180 at Bernstein SocGen Group

Thu, 27 Aug 2026 09:30:26 -0400

(Updated - August 27, 2026 9:30 AM EDT)

Bernstein SocGen Group analyst Eve Burstein raised the price target on Agilent (NYSE: A) to $180.00 (from $155.00) while maintaining an Outperform rating.

Agilent (A) PT Raised to $180 at TD Cowen

Thu, 27 Aug 2026 09:27:51 -0400

(Updated - August 27, 2026 9:27 AM EDT)

TD Cowen analyst Dan Brennan raised the price target on Agilent (NYSE: A) to $180.00 (from $155.00) while maintaining a Buy rating.

The analyst commented: "A's Strong F3Q (Pharma, CAM,China Drivers) Caps Off Solid Tools Earnings Season; We expect A's shares to react favorably post a broad-based top line / margin / & EPS beat. Organic growth of 7.3% beat by 2% led by Pharma (+12%), CAM (+7%), Instruments (HSD%) & China (+9%) - & margins shined (big beat). While A cited improving markets (good for Tools), execution is key with solid pricing, new

Agilent (A) PT Raised to $180 at TD Cowen

Thu, 27 Aug 2026 09:27:51 -0400

(Updated - August 27, 2026 9:27 AM EDT)

TD Cowen analyst Dan Brennan raised the price target on Agilent (NYSE: A) to $180.00 (from $155.00) while maintaining a Buy rating.

Agilent (A) PT Raised to $185 at RBC Capital

Thu, 27 Aug 2026 08:57:15 -0400

(Updated - August 27, 2026 8:57 AM EDT)

RBC Capital analyst Dan Leonard raised the price target on Agilent (NYSE: A) to $185.00 (from $155.00) while maintaining an Outperform rating.

The analyst commented: "Broad Beat, Pharma Leads, Product Cycles Firing; Our constructive view on Agilent is anchored by building product cycle momentum across key instrument platforms, exposure to drug manufacturing, and minimal aca/govt drag. The company's FYQ3 beat and guidance increase support our thesis. Agilent exceeded Street expectations, flagging strength in several product areas, early orders related to pharma reshoring, and strength in advanced materials. We've increased our forecasts to reflect the

Agilent (A) PT Raised to $185 at RBC Capital

Thu, 27 Aug 2026 08:57:15 -0400

(Updated - August 27, 2026 8:57 AM EDT)

RBC Capital analyst Dan Leonard raised the price target on Agilent (NYSE: A) to $185.00 (from $155.00) while maintaining an Outperform rating.

Agilent (A) PT Raised to $190 at JPMorgan

Thu, 27 Aug 2026 08:30:17 -0400

JPMorgan analyst Casey Woodring raised the price target on Agilent (NYSE: A) to $190.00 (from $180.00) while maintaining a Overweight rating.

Agilent (A) PT Raised to $180 at Stifel on Q3 Beat

Thu, 27 Aug 2026 07:31:57 -0400

Stifel analyst Daniel Arias raised the price target on Agilent (NYSE: A) to $180.00 (from $170.00) while maintaining a Buy rating.

The analyst commented, "Agilent delivered a 3Q beat that probably won't surprise those that have been keyed into Tools prints and trends this quarter, but is nonetheless a solid result that should have shares up in the morning. Strong growth in LC-MS (low double-digits, which drove HSD growth overall for instrumentation) and Advanced Therapeutics (up a robust ~30%) reflect positive trends in biopharma (including early reshoring orders), while semiconductor demand and PFAS testing were strong contributors in the applied setting.